Investor relations

We use innovative science to pursue novel treatments that address important medical challenges in neurological, autoimmune and rare diseases. Our therapies for multiple sclerosis and hemophilia are just the beginning.

New hemophilia-focused company on track to launch in early 2017

Find more information about Bioverativ, which will be an independent, publicly-traded company.

Events and webcasts

View our upcoming events and latest webcasts.

Stock information

Find Biogen’s current and historical stock information. 

NASDAQ: BIIB (Common Stock)

  • Volume
  • Today's Open $
  • Previous Close $
  • 52 Week High $
  • 52 Week Low $